(3,4-Dimethoxyphenyl)acetonitrile is a pharma grade API intended for tablet, capsule, granule, and injection manufacturing. The substance is a crystalline phenylacetonitrile derivative identified by CAS 93-17-4, molecular formula C₁₀H₁₁NO₂, molecular weight 177.20 g/mol, and IUPAC name 2-(3,4-dimethoxyphenyl)acetonitrile. Synonyms include homoveratronitrile and 3,4-dimethoxybenzyl cyanide. The material is supplied as an oral solid grade and an injectable grade under batch-specific certificates of analysis; both models share the same chemical identity but differ in particle size distribution, endotoxin control, and residual solvent acceptance criteria.

The pharma grade designation separates this product from technical-grade material through GMP controls aligned with ICH Q7, documented manufacturing history, and batch release against ICH Q3A, ICH Q3C, and ICH Q3D expectations. The molecule has two methoxy substituents and a neutral nitrile group, resulting in a poorly water-soluble crystalline solid with no readily ionizable centre over the gastrointestinal pH range. Consequently, oral and injectable formulation design depends on particle engineering, solid-state control, and solvent selection rather than salt formation or pH-driven solubility adjustment. Literature melting range for the pure form is commonly cited at 64–66 °C, and differential scanning calorimetry of pharma grade batches typically shows a sharp endotherm in this region when residual solvent and moisture are controlled.

Because no harmonized pharmacopeial monograph for this molecule is currently listed in USP–NF, Ph. Eur., or JP, the following release profile represents supplier-certified specifications referenced to general chapters. These values are verified on a batch-by-batch basis unless a written quality agreement states otherwise.

The impurity profile is typically monitored by reversed-phase HPLC with an octadecylsilane column and acetonitrile/water or methanol/water mobile phases. The main potential degradation and process-related substances are 3,4-dimethoxyphenylacetic acid, arising from nitrile hydrolysis, and residual 3,4-dimethoxybenzaldehyde from upstream synthesis. Residual aldehyde and cyanide-related process impurities are controlled because they affect downstream chemical conversion and long-term dosage-form stability. Batch release documentation includes retention time identity, relative response factors, and impurity trend data. Published data for this specific configuration is limited; therefore, impurity quantitation thresholds should be validated during analytical method transfer rather than assumed from compendial monographs.

For oral solid dose processing, the powder is blended with common diluents such as microcrystalline cellulose, spray-dried lactose, and pregelatinized starch in bin blenders or V-blenders. Because the active is often formulated at low dose, geometric dilution or pre-mixing with a portion of diluent is required to achieve consistent content uniformity. Blend uniformity is verified by HPLC or near-infrared analysis, and finished dosage units are tested under USP <905>. Tablets and capsules containing this molecule are usually dissolution-limited because of poor aqueous solubility; particle size reduction and wetting agent selection therefore have a greater effect on release than pH adjustment. Direct compression is feasible only when the API particle size is tightly controlled and the formulation contains a suitable flow aid such as colloidal silicon dioxide.

Granule processing requires attention to the nitrile substituent. Wet granulation at neutral pH and moderate temperature is generally tolerated for short residence times, but prolonged wet massing or elevated tray drying can increase hydrolysis-related impurities. Fluid-bed dryers with controlled inlet air temperature and minimized granulation time are usually preferred over long tray drying. Dry granulation by roller compaction can be used when aqueous exposure is a concern; however, the resulting granules must be evaluated for bulk density, tap density, and compressibility according to USP <616>. Production-scale roller compactors with fixed gap and roll pressure settings require API lots with consistent particle size, because variability in D50 can shift ribbon density and downstream tablet hardness.

What Limits the Use of This Nitrile in Aqueous Granulation and Terminal Sterilization?

The principal processing constraint is hydrolytic degradation of the nitrile group to the corresponding phenylacetic acid derivative. Aqueous granulation at neutral pH may be acceptable under short residence time, but terminal steam sterilisation at 121 °C in an aqueous formulation is not recommended without forced degradation data covering hydrolysis impurity formation. If an injectable solution or suspension is required, aseptic filtration with a non-aqueous co-solvent or a controlled low-temperature process is commonly used. Strongly alkaline buffer systems should be avoided during formulation development because benzyl nitriles are known to undergo base-catalysed hydrolysis. Strongly acidic conditions can also promote degradation over extended storage, although the rate at typical oral dosage-form pH may be slower. Published data for the specific hydrolytic kinetics of this molecule in finished injectable matrices is limited, so stability-indicating methods must be developed and forced degradation studies completed before final manufacturing parameters are fixed.

Material compatibility during processing includes evaluation of residual water, lubricant type, and packaging. Hydrolysis impurities can increase in formulations containing high moisture excipients or in packages with insufficient moisture barrier. HDPE containers with heat-sealed desiccant canisters are common for oral solid intermediates when the API is humidity-sensitive. For injectable-grade material, containers are typically closed with inert gas protection and supplied with endotoxin and bioburden certificates because the molecule is not intended for terminal autoclaving without formulation-specific data.

Particle-Size and Solid-State Controls for Solid and Parenteral Dose Manufacture

Particle size distribution is a critical material attribute for both oral and injectable models. Laser diffraction by USP <429> or sieve analysis by USP <786> is used to control the powder fraction. Mechanical milling on pin mills or hammer mills can generate amorphous surface domains and electrostatic charge; a nitrogen-fed fluid energy mill is commonly selected for micronisation because it reduces thermal and oxidative stress. Production experience shows that when a jet-milled API is discharged without humidity control, moisture uptake can increase particle cohesion and reduce flow through rotary tablet press feed frames. Therefore, containers should be closed and stored below 60% relative humidity, and the API should be conditioned to room temperature before opening. For low-dose direct compression formulas, a D90 above 100 µm may produce blend uniformity failures unless the API is pre-milled or pre-dispersed with a diluent of similar particle size.

For injectable formulations, the grade is supplied with reduced bioburden and controlled bacterial endotoxins. If the intended dosage form is a suspension, particle size must be defined relative to syringeability and tissue tolerability; if the intended dosage form is a solution, the API particle size is less critical than residual solvent, endotoxin, and particulate matter control. Non-aqueous injectable vehicles such as polyethylene glycol and propylene glycol may be evaluated for solubility and chemical stability. In all cases, filtration compatibility should be assessed because low-solubility neutral compounds can adsorb to sterilizing-grade membrane filters. Terminal sterilization of a non-aqueous vehicle may be possible, but the final formulation must be tested for nitrile degradation products under the proposed thermal cycle.

Compared with technical-grade material, the pharma grade product differs in manufacturing controls, impurity transparency, and batch documentation. A technical-grade lot may contain elevated residual solvents, aldehyde precursors, or elemental impurities that are not suitable for parenteral or oral pharmaceutical use. The pharma grade is released under a quality system referencing ISO 9001:2015 or equivalent, and the finished dosage form manufacturer retains responsibility for validation under 21 CFR Parts 210 and 211. Compared with unsubstituted phenylacetonitrile, the 3,4-dimethoxy derivative is crystalline at ambient temperature and has a higher melting point, reducing liquid-layer segregation in dry blends. Compared with alternative dimethoxy positional isomers, the 3,4-substitution pattern changes chromatographic retention and solid-state packing but does not remove the nitrile degradation risk. These differences make the pharma grade model suitable for controlled oral solid, granule, and injectable process trains when particle size, hydrolytic stability, and impurity limits are managed through the release specification and formulation design.